Catalyst Pharm Inc (CPRX) |
|
3.7 -0.01 (-0.27%)
|
01-27 02:46 |
|
Open: |
3.76 |
Pre. Close: |
3.71 |
|
High:
|
3.8 |
Low:
|
3.66 |
|
Volume:
|
1,351,481 |
Market Cap:
|
383M |
|
|
|
|
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.805 - 3.823 |
3.823 - 3.842 |
|
Low:
|
3.606 - 3.629 |
3.629 - 3.652 |
|
Close:
|
3.657 - 3.694 |
3.694 - 3.73 |
|
Technical analysis |
as of: 2021-01-26 4:42:31 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 4.44 One year: 5.18 |
| Support: |
Support1: 3.49 Support2: 3.30 |
| Resistance: |
Resistance1: 3.80 Resistance2: 4.44 |
| Pivot: |
3.57  |
| Moving Average: |
MA(5): 3.67 MA(20): 3.53
MA(100): 3.36 MA(250): 3.92 |
| MACD: |
MACD(12,26): 0.05 Signal(9): 0.03 |
| Stochastic oscillator: |
%K(14,3): 73.53 %D(3): 72.92 |
| RSI: |
RSI(14): 59.11 |
| 52-week: |
High: 5.28 Low: 2.55 Change(%): -14.5 |
| Average Vol(K): |
3-Month: 173431 10-Days: 153874 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.CPRX has closed below upper band by 10.7%. Bollinger Bands are 23.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 21 Jan 2021
Could The Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Ownership Structure Tell Us Something Useful? - Simply Wall St
Wed, 20 Jan 2021
Where Does Wall Street Think Catalyst Pharmaceuticals Inc (CPRX) Stock Will Go? - InvestorsObserver
Sun, 17 Jan 2021
Validea's Top Five Healthcare Stocks Based On David Dreman - 1/17/2021 - Nasdaq
Tue, 12 Jan 2021
What is Wall Street's Target Price for Catalyst Pharmaceuticals Inc (CPRX) Stock? - InvestorsObserver
Fri, 08 Jan 2021
CPRX: 3 Biotech Stocks on the Robinhood 100 to AVOID - StockNews.com
Thu, 07 Jan 2021
Catayst (CPRX) Provides Long-Term Portfolio Expansion Plans - Nasdaq
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Outperform |
Price to Earnings: |
Outperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
104 |
| Shares Float (M) |
86 |
|
% Held by Insiders
|
6.98 |
|
% Held by Institutions
|
69.58 |
|
Shares Short (K)
|
12,280 |
|
Shares Short P. Month (K)
|
13,440 |
Stock Financials |
|
EPS
|
0.670 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
1.510 |
|
Profit Margin
|
60.48 |
|
Operating Margin
|
34.43 |
|
Return on Assets (ttm)
|
18.7 |
|
Return on Equity (ttm)
|
60.9 |
|
Qtrly Rev. Growth
|
-5.1 |
|
Gross Profit (p.s.)
|
0.845 |
|
Sales Per Share
|
1.140 |
|
EBITDA (p.s.)
|
0.394 |
|
Qtrly Earnings Growth
|
218.00 |
|
Operating Cash Flow (M)
|
44 |
|
Levered Free Cash Flow (M)
|
30 |
Stock Valuations |
|
PE Ratio
|
5.52 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.45 |
|
Price to Sales
|
3.24 |
|
Price to Cash Flow
|
8.67 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
